Drug manufacturer GlaxoSmithKline (GSK), which is under investigation on suspicion that its employees bribed Chinese doctors, yesterday said the finance director for its local unit has been barred from leaving China.
Finance director Steve Nechelput has not been questioned or arrested and is free to travel within China, the British company said in a statement. It said it had been aware of the travel restrictions since the end of last month. Nechelput continues to work in his role as finance director for the company’s China unit.
Chinese police announced this week that they detained four GSK employees on suspicion of paying bribes to doctors, hospitals and others to encourage them to prescribe the company’s medications.
Police say the employees funneled as much as 3 billion yuan (US$490 million) through travel agencies and consulting firms to hide the source of bribes, according to Chinese news reports. Investigators have not said how much of that money was paid as bribes.
Xinhua news agency said the scheme appeared to be aimed at evading GSK’s internal controls meant to prevent bribery.
GSK has said it opposes bribery and was cooperating with the investigation.
On Wednesday, the Chinese State Food and Drug Administration launched a crackdown on misconduct in its pharmaceutical market, though it gave no indication it was linked to the GSK probe.
The drug regulator said the campaign is aimed at stamping out unauthorized drug production, improper online drug retailing and sales of fake traditional Chinese medicines.
The new Chinese leadership that took power in November last year has promised to improve China’s health system and rein in surging costs of medicine and medical care that are fueling public frustration.
China has suffered repeated scandals over fake or shoddy medications, some of which caused deaths and injuries. Regulators have launched repeated crackdowns on false advertising and other violations, but with limited success.
Also on Wednesday, a Chinese Ministry of Commerce spokesman warned that Chinese and foreign drug manufacturers would face “legal sanctions” for misconduct.
Meanwhile, the Cabinet’s planning agency is investigating production costs at 60 Chinese and foreign pharmaceutical manufacturers, according to state media, possibly a prelude to revising state-imposed price caps on key medications.
Poland is betting on a flood of investments and technology transfers from Taiwanese companies to reengineer its US$1 trillion economy. Polish Prime Minister Donald Tusk said yesterday that Poland will no longer be “just an assembly hub” as it pursues further investments from the likes of Foxconn Technology Group (富士康). The firm, whose full name is Hon Hai Precision Industry Co (鴻海精密), last month agreed to build electric vehicles (EVs) in the European Union nation and now could be a partner in a semiconductor venture, he said. The government’s aim is to boost manufacturing and the country’s high-tech chops in an era
Taiwan remained the sixth-largest net creditor nation in the world last year, despite a fall of more than 10 percent in its net international investment position (NIIP) over the year, the central bank said yesterday. The NIIP is the difference between a country’s external financial assets and its external financial liabilities. Taiwan’s external financial assets hit US$3.27 trillion at the end of last year, up US$275.75 billion or 9.2 percent from a year earlier, the central bank said in its annual NIIP report. The growth largely reflected an increase in holdings of overseas marketable securities by residents in Taiwan, as well as a
BAD FAITH LITIGATION? The two companies, owned by a California-based private equity firm, could be seeking licensing fees or a settlement payout with the suit Taiwan Intellectual Property Office (TIPO) Director-General Liao Cheng-wei (廖承威) said yesterday he suspected that two firms suing contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) for patent infringement are “patent trolls.” A patent troll refers to a company that buys patents not for manufacturing products, but to sue other companies for compensation, accusing them of using its patents. Patent trolls, formally called Non-Practicing Entities or Patent Assertion Entities, were responsible for more than 50 percent of lawsuits in the US last year, costing targeted businesses tens of billions of US dollars a year, according to the US-based LegalCharity Web site. Asked whether
RESTRICTION BREACH: ASML said that it denies ‘unfounded rumors regarding non-compliance with export controls concerning China,’ and enforces controls strictly US Secretary of Commerce Howard Lutnick in a series of recent meetings outlined concerns to Dutch chip-equipment giant ASML Holding NV’s senior leaders that one of its top-of-the-line machines might have made its way into China, in violation of US-led export restrictions. In the meetings, Lutnick expressed concern to ASML executives over the company’s extreme ultraviolet lithography (EUV) machines, people familiar with the talks said. EUV systems are used by firms such as Taiwan Semiconductor Manufacturing Co (台積電) to manufacture processors for the likes of Nvidia Corp and Apple Inc. ASML has never been allowed to ship them to China because of curbs
RSS